Michelle T Long1, Xiaoyu Zhang2, Hanfei Xu2, Ching-Ti Liu2, Kathleen E Corey3, Raymond T Chung3, Rohit Loomba4, Emelia J Benjamin5. 1. Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, MA. 2. Department of Biostatistics, Boston University, Boston, MA. 3. Liver Center, Gastroenterology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 4. Division of Gastroenterology, Department of Medicine and Division of Epidemiology, Department of Family and Preventive, University of California at San Diego, La Jolla, CA. 5. Evans Department of Medicine, Whitaker Cardiovascular Institute and Cardiology Section, Boston University School of Medicine, Boston, MA.
Abstract
BACKGROUND AND AIMS: NAFLD is increasing in prevalence and will soon be the most common chronic liver disease. Liver stiffness, as assessed by vibration-controlled transient elastography (VCTE), correlates with hepatic fibrosis, an important predictor of liver-related and all-cause mortality. Although liver fat is associated with cardiovascular risk factors, the association between hepatic fibrosis and cardiovascular risk factors is less clear. APPROACH AND RESULTS: We performed VCTE, assessing controlled attenuation parameter (CAP; measure of steatosis) and liver stiffness measurement (LSM) in 3,276 Framingham Heart Study adult participants (53.9% women, mean age 54.3 ± 9.1 years) presenting for a routine study visit. We performed multivariable-adjusted logistic regression models to determine the association between LSM and obesity-related, vascular-related, glucose-related, and cholesterol-related cardiovascular risk factors. The prevalence of hepatic steatosis (CAP ≥ 290 dB/m) was 28.8%, and 8.8% had hepatic fibrosis (LSM ≥ 8.2 kPa). Hepatic fibrosis was associated with multiple cardiovascular risk factors, including increased odds of obesity (OR, 1.82; 95% CI, 1.35-2.47), metabolic syndrome (OR, 1.49; 95% CI 1.10-2.01), diabetes (OR, 2.67; 95% CI, 1.21-3.75), hypertension (OR, 1.52; 95% CI, 1.15-1.99), and low high-density lipoprotein cholesterol (OR, 1.47; 95% CI, 1.09-1.98), after adjustment for age, sex, smoking status, alcohol drinks/week, physical activity index, aminotransferases, and CAP. CONCLUSIONS: In our community-based cohort, VCTE-defined hepatic fibrosis was associated with multiple cardiovascular risk factors, including obesity, metabolic syndrome, diabetes, hypertension, and high-density lipoprotein cholesterol, even after accounting for covariates and CAP. Additional longitudinal studies are needed to determine if hepatic fibrosis contributes to incident cardiovascular disease risk factors or events.
BACKGROUND AND AIMS: NAFLD is increasing in prevalence and will soon be the most common chronic liver disease. Liver stiffness, as assessed by vibration-controlled transient elastography (VCTE), correlates with hepatic fibrosis, an important predictor of liver-related and all-cause mortality. Although liver fat is associated with cardiovascular risk factors, the association between hepatic fibrosis and cardiovascular risk factors is less clear. APPROACH AND RESULTS: We performed VCTE, assessing controlled attenuation parameter (CAP; measure of steatosis) and liver stiffness measurement (LSM) in 3,276 Framingham Heart Study adult participants (53.9% women, mean age 54.3 ± 9.1 years) presenting for a routine study visit. We performed multivariable-adjusted logistic regression models to determine the association between LSM and obesity-related, vascular-related, glucose-related, and cholesterol-related cardiovascular risk factors. The prevalence of hepatic steatosis (CAP ≥ 290 dB/m) was 28.8%, and 8.8% had hepatic fibrosis (LSM ≥ 8.2 kPa). Hepatic fibrosis was associated with multiple cardiovascular risk factors, including increased odds of obesity (OR, 1.82; 95% CI, 1.35-2.47), metabolic syndrome (OR, 1.49; 95% CI 1.10-2.01), diabetes (OR, 2.67; 95% CI, 1.21-3.75), hypertension (OR, 1.52; 95% CI, 1.15-1.99), and low high-density lipoprotein cholesterol (OR, 1.47; 95% CI, 1.09-1.98), after adjustment for age, sex, smoking status, alcohol drinks/week, physical activity index, aminotransferases, and CAP. CONCLUSIONS: In our community-based cohort, VCTE-defined hepatic fibrosis was associated with multiple cardiovascular risk factors, including obesity, metabolic syndrome, diabetes, hypertension, and high-density lipoprotein cholesterol, even after accounting for covariates and CAP. Additional longitudinal studies are needed to determine if hepatic fibrosis contributes to incident cardiovascular disease risk factors or events.
Authors: Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo Journal: Lancet Date: 2014-11-07 Impact factor: 79.321
Authors: Hye Won Lee; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang Joon Kim; Kwang-Hyub Han Journal: Dig Dis Sci Date: 2017-05-18 Impact factor: 3.199
Authors: Winston Dunn; Ronghui Xu; Deborah L Wingard; Christopher Rogers; Paul Angulo; Zobair M Younossi; Jeffrey B Schwimmer Journal: Am J Gastroenterol Date: 2008-08-05 Impact factor: 10.864
Authors: Vincent Wai-Sun Wong; Julien Vergniol; Grace Lai-Hung Wong; Juliette Foucher; Henry Lik-Yuen Chan; Brigitte Le Bail; Paul Cheung-Lung Choi; Mathurin Kowo; Anthony Wing-Hung Chan; Wassil Merrouche; Joseph Jao-Yiu Sung; Victor de Lédinghen Journal: Hepatology Date: 2010-02 Impact factor: 17.425
Authors: Neal S Parikh; Insu Koh; Lisa B VanWagner; Mitchell S V Elkind; Neil A Zakai; Mary Cushman Journal: J Stroke Cerebrovasc Dis Date: 2021-04-16 Impact factor: 2.677
Authors: Neeta B Amin; Amanda Darekar; Quentin M Anstee; Vincent Wai-Sun Wong; Frank Tacke; Manoli Vourvahis; Douglas S Lee; Michael Charlton; Naim Alkhouri; Atsushi Nakajima; Carla Yunis Journal: BMJ Open Date: 2022-03-30 Impact factor: 2.692
Authors: Fredrik Åberg; Katri Kantojärvi; Ville Männistö; Anna But; Veikko Salomaa; Teemu Niiranen; Martti Färkkilä; Panu Luukkonen; Satu Männistö; Annamari Lundqvist; Markus Perola; Antti Jula Journal: Sci Rep Date: 2022-09-16 Impact factor: 4.996
Authors: Sebastian Niezen; Elliot B Tapper; Hirsh Trivedi; Michelle Lai; Michael P Curry; Kenneth J Mukamal; Z Gordon Jiang Journal: Hepatol Commun Date: 2021-10-25